The FDA has approved tavapadon (JUVMO), a once-daily selective D1/D5 dopamine receptor agonist for adults with Parkinson's disease, usable with or without levodopa. In placebo-controlled trials, patients with motor fluctuations gained 1.7 hours of daily 'on' time without troublesome dyskinesia versus 0.6 hours on placebo, and early-stage patients improved 22-23% on daily-function scores while placebo declined. The approval targets a different receptor family than the D2/D3 agonists that have defined the class for decades.
Key Points
- First selective D1/D5 dopamine agonist approved for Parkinson's disease
- Added 1.7 hours daily 'on' time versus 0.6 placebo
- Side effects include hallucinations, orthostatic hypotension, impulse-control disturbances
Longevity Analysis
Parkinson's management has long been a negotiation between motor control and the cost of achieving it, with roughly 70% of patients escalating levodopa within the first year and accumulating dyskinesia risk as they do. Targeting a distinct receptor family offers a route to preserve movement capacity while delaying that escalation — relevant because mobility, postural stability and autonomic regulation are among the strongest determinants of functional lifespan in neurodegenerative disease. The side-effect profile, which spans blood pressure regulation on standing, perception and impulse control, means benefit depends on close interpretation of individual response rather than dose alone.
Original published by Longevity.Technology, by Kyle Umipig.